El gen CDX2 es el homólogo humano a un gen caudal homeobox de Drosophila que codifica un factor de transcripción expresado en las células epiteliales del intestino de los mamíferos adultos. La proteína CDX2 participa en la regulación de la proliferación celular, así como de la diferenciación de las células epiteliales del intestino.
CDX2 se detecta por inmunohistoquímica en el núcleo de las células epiteliales de intestino delgado y grueso (células absortivas, caliciformes, endocrinas y de Paneth), en el epitelio pancreático y en distintas neoplasias: adenocarcinoma colorectal (86-100%) primario o metastásico, adenocarcinoma gástrico (22-90%), tumor carcinoide gastrointestinal (30-70%), adenocarcinoma mucinoso de ovario (11-100%), adenocarcinoma de vejiga urinaria (47-100%), carcinoma de páncreas (32-60%) y raramente en carcinoma de próstata (2-6%).
El anticuerpo CDX2, junto con CK7 y CK20, resulta de especial utilidad para el diagnóstico de tumores metastásicos del tracto gastrointestinal. En combinación con TTF-1 permite discriminar entre adenocarcinoma de origen digestivo o pulmonar.
BIBLIOGRAFÍA
•Moskaluk CA et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-9.
•Barbareschi M et al CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 2003;27:141-9.
•Werling RW et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
•Kaimaktchiev V et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-9.
•Suh N et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005;18:1217-22.
•Saqi A et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404.
•Herawi M et al. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol 2007;38:72-8.
•Lin X et al. Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin. Appl Immunohistochem Mol Morphol 2007;15:407–414.
•Liu Q et al. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cáncer. Modern Pathology 2007;20, 1286–97.
•Park JC et al. Immunoprofile of adenocarcinomas of the endometrium, endocervix ans ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol 2009;17(1):8-11.
•Saad RS et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2009;17(3):196-201.
Fuente: http://www.histopat.es/tec-inm-banco.htm
CDX2 se detecta por inmunohistoquímica en el núcleo de las células epiteliales de intestino delgado y grueso (células absortivas, caliciformes, endocrinas y de Paneth), en el epitelio pancreático y en distintas neoplasias: adenocarcinoma colorectal (86-100%) primario o metastásico, adenocarcinoma gástrico (22-90%), tumor carcinoide gastrointestinal (30-70%), adenocarcinoma mucinoso de ovario (11-100%), adenocarcinoma de vejiga urinaria (47-100%), carcinoma de páncreas (32-60%) y raramente en carcinoma de próstata (2-6%).
El anticuerpo CDX2, junto con CK7 y CK20, resulta de especial utilidad para el diagnóstico de tumores metastásicos del tracto gastrointestinal. En combinación con TTF-1 permite discriminar entre adenocarcinoma de origen digestivo o pulmonar.
BIBLIOGRAFÍA
•Moskaluk CA et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-9.
•Barbareschi M et al CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. Am J Surg Pathol 2003;27:141-9.
•Werling RW et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10.
•Kaimaktchiev V et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-9.
•Suh N et al. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod Pathol 2005;18:1217-22.
•Saqi A et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005;123:394-404.
•Herawi M et al. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol 2007;38:72-8.
•Lin X et al. Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin. Appl Immunohistochem Mol Morphol 2007;15:407–414.
•Liu Q et al. CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cáncer. Modern Pathology 2007;20, 1286–97.
•Park JC et al. Immunoprofile of adenocarcinomas of the endometrium, endocervix ans ovary with mucinous differentiation. Appl Immunohistochem Mol Morphol 2009;17(1):8-11.
•Saad RS et al. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl Immunohistochem Mol Morphol 2009;17(3):196-201.
Fuente: http://www.histopat.es/tec-inm-banco.htm
